| ［1］ |
Fang W, Yang Y, Ma Y, et al. Camrelizumab （SHR⁃1210） alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single⁃arm, phase 1 trials［J］. Lancet Oncol, 2018,19（10）:1338⁃1350. doi: 10.1016/S1470⁃2045（18）30495⁃9.
|
| ［2］ |
Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open⁃label, parallel⁃group, randomised, phase 2 trial［J］. Lancet Oncol, 2020,21（4）:571⁃580. doi: 10.1016/S1470⁃2045（20）30011⁃5.
|
| ［3］ |
Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial［J］. J Hematol Oncol, 2020,13（1）:47. doi: 10.1186/s13045⁃020⁃00886⁃2.
|
| ［4］ |
Finlay W, Coleman JE, Edwards JS, et al. Anti⁃PD1 ′SHR⁃1210′ aberrantly targets pro⁃angiogenic receptors and this polyspecificity can be ablated by paratope refinement［J］. MAbs, 2019,11（1）:26⁃44. doi: 10.1080/19420862.2018.1550321.
|
| ［5］ |
Xu J, Zhang Y, Jia R, et al. Anti⁃PD⁃1 antibody SHR⁃1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open⁃label, dose escalation and expansion study［J］. Clin Cancer Res, 2019,25（2）:515⁃523. doi: 10.1158/1078⁃0432.CCR⁃18⁃2484.
|
| ［6］ |
Lim EH, Kim HR, Im M, et al. Eruptive cherry hemangioma⁃like lesions developing in a patient with multiple myeloma［J］. J Am Acad Dermatol, 2013,68（4）:e137⁃e138. doi: 10.1016/j.jaad.2012. 09.045.
|
